marches9 %Novartis shares dropped nearly 9% following repeated clinical failures

Novartis shares plummet after two consecutive clinical failures

Novartis shares dropped nearly 9% following repeated clinical failures.

Published 2h1 sourceImportant

≈ 16sSpeed

The fact

A treatment for a neuromuscular disease and another project failed to meet their goals.

These setbacks raise questions about the pharmaceutical giant's research strategy.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on September 8, 2026